{"id":37849,"date":"2026-07-16T18:00:00","date_gmt":"2026-07-16T16:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=931ae56b5efd08d0e4b69e221ae8d4d0"},"modified":"2026-07-16T18:00:00","modified_gmt":"2026-07-16T16:00:00","slug":"nucleai-expands-its-strategic-partnership-with-university-of-glasgow-to-advance-access-to-its-multimodal-tissue-intelligence-ai-platform","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=37849","title":{"rendered":"Nucleai Expands its Strategic Partnership with University of Glasgow to Advance Access to Its Multimodal Tissue Intelligence AI Platform"},"content":{"rendered":"

TEL AVIV, Israel--(BUSINESS WIRE)--#AIpathology<\/a>--Nucleai, a leader in AI-powered tissue intelligence, today announced expanded access to its multimodal spatial analytics platform, through a partnership with the University of Glasgow\u2019s Spatial Pathology Analytical Research and Clinical Integration (SPARC) Lab.<\/p><\/a><\/a>

\nThis collaboration extends access to Nucleai\u2019s platform for multiplex image analysis for academic and translational research, providing Glasgow researchers a scalable, cross-instrument workflow that transforms complex imaging data into structured, quantitative spatial insights. Through the partnership, Prof. Nigel Jamieson and the SPARC Lab will apply Nucleai\u2019s end-to-end AI platform to analyze multiplex immunofluorescence (mIF) imaging data. The collaboration will enable continued enhancement of the Nucleai platform through access to unique SPARC data cohorts within a secure and governed framework.<\/p>

\nWhile spatial biology technologies have advanced rapidly, analytical throughput remains a critical bottleneck. Converting raw multiplex tissue images into validated insights can take many months, limiting experimental throughput and slowing discovery. Nucleai\u2019s platform automates image normalization, cell phenotyping and spatial feature generation, reducing tissue-to-insight timelines from months to weeks and enabling research teams to run more experiments with greater consistency across cohorts.<\/p>

\nThe impact is not just speed, but also more consistent analytics. This enables more experiments with deeper biological understanding, and stronger links between spatial biology, drug development, and precision diagnostics. By removing the image analysis bottleneck, Nucleai allows spatial biology programs to operate at the pace of their scientific questions rather than the pace of their analytical infrastructure.<\/p>

\n\u201cSpatial biology will only deliver on its promise if insight moves as fast as data generation,\u201d said Avi Veidman, CEO of Nucleai. \u201cBy compressing the tissue-to-insight cycle from months to weeks, we are changing how research is done - enabling more experimentation, deeper understanding of biology, and faster translation into better drugs and precision diagnostics. We built Nucleai as a tissue intelligence platform layer that amplifies the value of spatial technologies across instruments and modalities.\u201d<\/p>

\nProf. Jamieson added: \u201cNucleai\u2019s platform allows us to connect high-dimensional spatial imaging with clinical outcomes far more efficiently, opening new opportunities for discovery and translational research.\u201d<\/p>

\nThe University of Glasgow partnership is the first step in Nucleai\u2019s broader effort to expand platform access to academic and translational groups working with spatial proteomics and multimodal tissue data. Nucleai is actively exploring collaborations with institutions working with unique spatial datasets that combine advanced imaging with longitudinal patient outcomes to create differentiated discovery and translational assets.<\/p>

\nInstitutions and partners interested in platform access and data-driven collaboration are encouraged to engage with Nucleai.<\/p>

\nAbout Nucleai<\/b><\/p>

\nNucleai is an AI-powered tissue intelligence company applying tissue imaging to understand the biological context of disease. Its multimodal platform integrates advanced spatial imaging, including proteomics and transcriptomics, with clinical data to uncover actionable translational insights for drug and diagnostics development. Nucleai partners with leading pharmaceutical, diagnostics, and academic institutions worldwide. Learn more at www.nucleai.ai<\/a>.<\/p>

\nAbout the University of Glasgow and SPARC<\/b><\/p>

\nThe University of Glasgow<\/b> is a world-leading research institution and a global leader in spatial proteomics and transcriptomics. Its SPARC Lab<\/b> (Spatial Pathology Analytical Research and Clinical Integration) is a center of excellence in multiplex imaging and computational pathology, driving innovation in translational and precision medicine.<\/p> Contacts<\/b>

\nMedia Contacts\n\n<\/b>For Nucleai<\/b>press@nucleai.ai<\/a>\nFor University of Glasgow<\/b>Communications & Public Affairs Office\nElizabeth.McMeekin@glasgow.ac.uk<\/a>Ali.Howard@glasgow.ac.uk<\/a><\/p>","protected":false},"excerpt":{"rendered":"

TEL AVIV, Israel–(BUSINESS WIRE)–#AIpathology–Nucleai, a leader in AI-powered tissue intelligence, today announced expanded access to its multimodal spatial analytics platform, through a partnership with the University of Glasgow\u2019s Spatial Pathology…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-37849","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/37849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37849"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/37849\/revisions"}],"predecessor-version":[{"id":37850,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/37849\/revisions\/37850"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}